#8 Targeted cancer therapies

Overview

This involves using second generation, small molecule tyrosine kinase inhibitors to block or modulate disease and provide treatments for advanced cancers, such as renal cell carcinoma.
 
An evolving success, with significant advances already reported. Lapatnib gained FDA approval in 2007 for patients with advanced, metastatic breast cancer that is HER2 positive.

Where Are They Now

This involves using second generation, small molecule tyrosine kinase inhibitors to block or modulate disease and provide treatments for advanced cancers, such as renal cell carcinoma. This technology has been an important advance with several agents in this genre that are either in clinical trials or that have been approved for a variety of cancers including leukemia, pancreatic, breast, lung, and renal. Research is currently being conducted on new drug compounds as well as ways to improve existing drugs through combination therapies and new ways to administer them.

The FDA has granted approval for several targeted cancer therapies against various types of cancers, with some drugs receiving approval to treat more than one cancer.

Get In Touch With Us